TABLE 4.
Clinical application of natural drugs in patients with HF and T2DM.
| Drug | Clinical application | References | |||||
|---|---|---|---|---|---|---|---|
| Clinic types of experiments | Patients | Number of examinees (n) | Drug usage and dosage | Usage time | Main results and conclusion | ||
| SF | / | Patients with chronic pulmonary heart disease and HF | n = 31 | Venous drop, SF and glucose injection 200 ml (200 mg), q.d. | 10 days | In the SF treatment group, 28 cases were markedly effective, with a total effective rate of 90.3%. Most patients’ symptoms were improved, blood gas indexes were normal or improved, and no adverse reactions occurred. | Song (2007) |
| A randomized controlled clinical trial | Patients with diabetic cardiomyopathy | n = 60 | i.v.gtt., sodium ferulate injection (0.3 g), q.d. | 30 days | In the SF group, EF and E peak/A peak were significantly higher after treatment than before treatment. SF combined with basic medication and insulin subcutaneous injection can effectively reduce blood lipids, improve heart function, and effectively alleviate the symptoms of DCM. | Fengxiang (2014) | |
| TMP | / | DM patients | n = 16 | i.v.gtt., TMP injection (LJ) 250 ml (5 mg/kg), q.d. | 20 days | Whole blood viscosity at 3.75 s shear rate was decreased, ADP-induced PA was decreased, and ED was slightly changed. It indicated that TMP could be a potential medication to ameliorate or prevent chronic vascular complications in diabetes. | Zhao et al. (1989) |
| / | Patients with chronic congestive HF | n = 84 | i.v.gtt., Astragalus injection 250 ml q.d., LJ (400 mg) 250 ml q.d. | 14 days | The combination of TMP injection and Astragalus membranaceus is more effective in the treatment of HF and can significantly improve the symptoms of HF. | Zhen and Faxiang (2011) | |
| Resveratrol | / | HF patients | n = 59 | p.o., resveratrol 4 mg every night | 2 months | Serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and CRP were all reduced to varying degrees, while LVEF was significantly increased, and the number of hospitalizations, total days, and mortality were reduced compared with those in the control group. | Guoping et al. (2005) |
| A randomized, double-blind, placebo-controlled trial | Patients with T2DM and coronary heart disease (CHD) | n = 56; resveratrol therapy group (n = 28), placebo group (n = 28) | p.o., resveratrol 500 mg/day | 4 weeks | Our-week supplementation of resveratrol in patients with T2DM and CHD had beneficial effects on glycemic control, HDL-cholesterol levels, the total/HDL-cholesterol ratio, and TAC and MDA levels. | Hoseini et al. (2019) | |